ImmunoPET to help stratify patients for targeted therapies and to improve drug development.
作者信息
Kraeber-Bodere Françoise, Bailly Clément, Chérel Michel, Chatal Jean-François
机构信息
Inserm U892, CNRS UMR 6299, University Hospital-ICO-CRCNA, Nantes-Saint-Herblain, France.
Groupement d'Intérêt Public Arronax, University of Nantes, Nantes, France.
出版信息
Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2166-2168. doi: 10.1007/s00259-016-3458-6. Epub 2016 Aug 18.
Abstract
摘要
相似文献
1
ImmunoPET to help stratify patients for targeted therapies and to improve drug development.
Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2166-2168. doi: 10.1007/s00259-016-3458-6. Epub 2016 Aug 18.
2
Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology.
J Clin Oncol. 2012 Nov 1;30(31):3884-92. doi: 10.1200/JCO.2012.42.4887. Epub 2012 Sep 17.
3
Copper-64-immunoPET imaging: bench to bedside.
Q J Nucl Med Mol Imaging. 2020 Dec;64(4):356-363. doi: 10.23736/S1824-4785.20.03310-5. Epub 2020 Oct 12.
4
Emerging role of immunoPET in receptor targeted cancer therapy.
Curr Drug Deliv. 2011 Jan;8(1):70-8. doi: 10.2174/156720111793663589.
5
Molecular Imaging of Immunotherapy Targets in Cancer.
J Nucl Med. 2016 Oct;57(10):1487-1492. doi: 10.2967/jnumed.116.177493. Epub 2016 Jul 28.
6
ImmunoPET: Concept, Design, and Applications.
Chem Rev. 2020 Apr 22;120(8):3787-3851. doi: 10.1021/acs.chemrev.9b00738. Epub 2020 Mar 23.
7
Radiochemistry, Production Processes, Labeling Methods, and ImmunoPET Imaging Pharmaceuticals of Iodine-124.
Molecules. 2021 Jan 14;26(2):414. doi: 10.3390/molecules26020414.
8
The chemical tool-kit for molecular imaging with radionuclides in the age of targeted and immune therapy.
Cancer Imaging. 2021 Jan 30;21(1):18. doi: 10.1186/s40644-021-00385-8.
9
Antibody positron emission tomography imaging in anticancer drug development.
J Clin Oncol. 2015 May 1;33(13):1491-504. doi: 10.1200/JCO.2014.57.8278. Epub 2015 Mar 16.
10
PET/Computed Tomography Using New Radiopharmaceuticals in Targeted Therapy.
PET Clin. 2015 Oct;10(4):495-505. doi: 10.1016/j.cpet.2015.05.007. Epub 2015 Jul 3.
引用本文的文献
1
Preclinical evaluation of a brain penetrant PARP PET imaging probe in rat glioblastoma and nonhuman primates.
Eur J Nucl Med Mol Imaging. 2023 Jun;50(7):2081-2099. doi: 10.1007/s00259-023-06162-y. Epub 2023 Feb 28.
2
FDG-PET/CT in Lymphoma: Where Do We Go Now?
Cancers (Basel). 2021 Oct 18;13(20):5222. doi: 10.3390/cancers13205222.
3
ImmunoPET in Multiple Myeloma-What? So What? Now What?
Cancers (Basel). 2020 Jun 4;12(6):1467. doi: 10.3390/cancers12061467.
4
Therapeutic and Diagnostic Antibodies to CD146: Thirty Years of Research on Its Potential for Detection and Treatment of Tumors.
Antibodies (Basel). 2017 Nov 5;6(4):17. doi: 10.3390/antib6040017.
5
Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture.
Cancers (Basel). 2019 Aug 31;11(9):1282. doi: 10.3390/cancers11091282.
6
Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches.
Front Med (Lausanne). 2019 Jun 4;6:124. doi: 10.3389/fmed.2019.00124. eCollection 2019.
7
Sensitivity of pretargeted immunoPET using Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with FDG PET-CT.
Oncotarget. 2018 Jun 8;9(44):27502-27513. doi: 10.18632/oncotarget.25514.
8
Noninvasive PET Imaging of T cells.
Trends Cancer. 2018 May;4(5):359-373. doi: 10.1016/j.trecan.2018.03.009. Epub 2018 Apr 17.
9
ImmunoPET imaging of CD38 in murine lymphoma models using Zr-labeled daratumumab.
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1372-1381. doi: 10.1007/s00259-018-3941-3. Epub 2018 Feb 15.
10
Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.
Cancer Res. 2018 Apr 1;78(7):1820-1832. doi: 10.1158/0008-5472.CAN-17-1958. Epub 2018 Jan 23.
本文引用的文献
1
ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer.
Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2169-2179. doi: 10.1007/s00259-016-3442-1. Epub 2016 Jun 25.
2
Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?
Front Pharmacol. 2016 May 24;7:131. doi: 10.3389/fphar.2016.00131. eCollection 2016.
3
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
Ann Oncol. 2016 Apr;27(4):619-24. doi: 10.1093/annonc/mdv577. Epub 2015 Nov 23.
4
89Zr-cetuximab PET imaging in patients with advanced colorectal cancer.
Oncotarget. 2015 Oct 6;6(30):30384-93. doi: 10.18632/oncotarget.4672.
5
Tumorigenesis: it takes a village.
Nat Rev Cancer. 2015 Aug;15(8):473-83. doi: 10.1038/nrc3971. Epub 2015 Jul 2.
6
TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET.
J Nucl Med. 2015 Sep;56(9):1310-4. doi: 10.2967/jnumed.115.154401. Epub 2015 Jul 1.
7
Pilot study of (89)Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer.
EJNMMI Res. 2014 Dec;4(1):35. doi: 10.1186/s13550-014-0035-5. Epub 2014 Aug 2.
8
Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.
Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1304-14. doi: 10.1007/s00259-015-3025-6. Epub 2015 Mar 20.
9
Antibody positron emission tomography imaging in anticancer drug development.
J Clin Oncol. 2015 May 1;33(13):1491-504. doi: 10.1200/JCO.2014.57.8278. Epub 2015 Mar 16.
10
Tumor immunotargeting using innovative radionuclides.
Int J Mol Sci. 2015 Feb 11;16(2):3932-54. doi: 10.3390/ijms16023932.
Zotero 插件